Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer
Funaki, H.; Miura, S.; Morioka, E.; Kaida, D.; Ohnishi, T.; Ohno, Y.; Tomita, Y.; Noguchi, M.; Fujita, H.; Kinami, S.; Nakano, Y.; Ueda, N.; Kosaka, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 2384-2386
2014
ISSN/ISBN: 0385-0684 PMID: 25731531 Document Number: 676003
There is no standard regimen after failure of 5-fluorouracil and cisplatin-based first-line chemotherapy in patients with advanced or recurrent esophageal cancer. The feasibility of combination chemotherapy with docetaxel (DOC) and nedaplatin (CDGP) for these patients was retrospectively evaluated. Patients received DOC (30 mg/m² intra- venously) and CDGP (30-40 mg/m² intravenously) on days 1 and 15 of each 4-week period. The efficacy and toxicity of combination chemotherapy with DOC and CDGP in 13 patients was analyzed. The patients received a median of 2 cycles of treatment(range, 1-23). The response and disease control rates were 8% and 54%, respectively. Grade 3 or 4 hematological toxicities were neutropenia, anemia, and thrombocytopenia, observed in 4(31%), 11(15%), and 2 patients (15%), respectively. Non-hematological toxicity, anorexia, was detected in only 1 patient(8%). No treatment-related death was observed. The median progression-free survival and overall survival were 3.2 and 11.6 months, respectively. Combination chemotherapy with DOC and CDGP is considered a feasible regimen for refractory esophageal cancer.